Healthcare information firm ConcertAI introduced a multi-year settlement with pharmaceutical and biotechnology large Bayer to make the most of ConcertAI’s Translational360 and AI SaaS choices.
The choices use AI and machine learning-acquired insights to hurry up medical improvement in precision oncology.
The settlement goals to make the most of ConcertAI’s Translational360 providing, an built-in research-level longitudinal medical molecular database that harnesses the CancerLinQ community of anonymized most cancers affected person information from greater than 9 million data from all 50 states.
Translational360 incorporates “medical, genomic, transcriptomic and whole-slide imaging from complete molecular testing for deep phenotypical and genomic insights.”
Transcriptomics permits researchers to grasp illness molecular mechanisms, the idea of affected person response and inter-patient flexibility, which is essential for growing new therapeutics.
Combining built-in information options and AI will enable for choosing applications with the best chance of success and design trials influenced by multimodal, multi-genomic and transcriptomic information and AI.
“This partnership builds on a multi-year historical past of working collectively and is exclusive in providing each tissue and liquid biopsy molecular information, permitting insights into patterns of therapy response, acquisition of resistance, AI modeling of possible success and profit, informing program precedence and medical research design,” Jeff Elton, CEO of ConcertAI, mentioned in an announcement.
THE LARGER TREND
Final 12 months, ConcertAI named Dhiraj Carumbay as senior vp and basic supervisor of the corporate’s TeraRecon enterprise.
Carumbay managed enterprise models at RadNet, Amazon AWS, Philips Healthcare, Fujifilm and GE HealthCare. At AWS, he oversaw Amazon’s cloud options for the healthcare and life-sciences industries. Earlier than that, he held enterprise management and international product roles at GE HealthCare.
In 2023, ConcertAI expanded its partnership with Caris Life Sciences. The businesses collectively created a database to generate insights to advance precision medication, medical trial administration and therapeutic improvement.
The companions developed a database that leveraged each corporations’ medical, molecular and multimodal information to allow teachers and biopharma researchers to realize insights for oncology-focused precision medication, medical trial administration and therapeutic improvement.
In 2022, ConcertAI scored $150 million in Sequence C funding. The spherical bumped the then-five-year-old firm’s valuation to $1.9 billion. As a part of the deal, Sixth Avenue’s managing director, Adam Kaye, joined ConcertAI’s board, and managing director Lee Mooney was named a board observer.
In 2024, GenAI radiology workflow firm Rad AI and Bayer collaborated to deliver Rad AI’s expertise to the multinational pharmaceutical and biotechnology firm’s Calantic Digital Answer clients.
Calantic is a vendor-neutral cloud-based market of AI-enabled radiology apps aimed toward automating routine radiology duties. Rad AI affords radiologists generative AI instruments to assist streamline workflows, together with doctor dictation and follow-up care administration choices.
That very same 12 months, Google Cloud and Bayer partnered to develop AI functions aimed toward decreasing radiologist burnout and growing efficiencies in diagnoses.
Bayer expanded its innovation platform utilizing Google Cloud expertise, together with its generative AI instruments. Different instruments out there on the platform embody Google Cloud’s Vertex AI, BigQuery, Healthcare API and Chronicle. The providing was supposed to assist organizations construct scalable and compliant AI-enabled software program for medical imaging whereas making certain information safety.
